BOLD
$1.15
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Recent News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Here's Why We're Watching Boundless Bio's (NASDAQ:BOLD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Boundless Bio, Inc. (BOLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).